Skip to main content

Asbestos Ban: EPA Officials Ignore EPA Experts

Asbestos Ban: EPA Officials Ignore EPA Experts

Asbestos Ban: EPA Officials Ignore EPA Experts

Introduction

According to the letter dated August 10, 2018, U.S. Environmental Protection Agency (EPA) experts had warned about risks from exposure to asbestos which was ignored by EPA officials.

The report came after the EPA's refusal to put a ban on asbestos last month, despite its alleged links to a number of serious and life-threatening health risks, including mesothelioma, lung cancer, asbestosis, and other ailments. EPA officials objected, claiming they only considered lung cancer and mesothelioma as potential asbestos harms and the “new uses” of asbestos could be safer.

J&J is facing nearly 14,000 talcum powder lawsuits, each raising a common allegation that asbestos exposure from the company’s talc-based products causes ovarian cancer or mesothelioma. Hon. Freda L. Wolfson, U.S.D.J./ Hon. Lois H. Goodman, U.S.M.J. overlooks J&J's talcum powder multidistrict litigation (MDL No. 2738; In Re: Johnson & Johnson Talcum Powder Products Marketing, Sales Practices, and Products Liability Litigation) in the District of New Jersey.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Attorneys Seek Reconsideration of Talc MDL Daubert Ruling

Categories: General

Plaintiffs’ attorneys are urging the U.S. District Judge overseeing the talcum powder lawsuit MDL to reconsider a recent decision for a second round…

Philips resolves DreamStation suits for $1.1B

Categories: Settlements

Dutch medical technology company Philips has finalized a $1.1 billion settlement in the United States to address lawsuits concerning faulty…

FDA OKs Generic OTC Naloxone Spray Approved by FDA

Categories: FDA Related

The FDA has granted approval for Amneal Pharmaceuticals to release a generic 4 mg naloxone hydrochloride nasal spray for over-the-counter (OTC) use, an announcement made in a press release.

Our Legal Drafting Services    
start @ $25 per hour.